Course: Should I Treat This Patient With Geographic Atrophy? Weighing Benefits and Burden of Treatment With Complement Inhibitors
CME Credits: 0.50
Released: 2025-05-30
Geographic atrophy (GA) is a progressive disease that can cause blindness and loss of independence. Recent advances in imaging and the approval of pharmacologic therapies targeting the complement cascade have created new opportunities to slow disease progression; however, these therapies are associated with an increased risk of neovascular complications and unanswered questions about which patients should be treated. To help specialists interpret and apply the growing body of evidence in patient selection practices, this point-counterpoint digital activity uses case-based discussions to frame differing perspectives around complex clinical questions, helping learners critically review the risk-benefit profiles of novel agents and optimally select GA patients who may qualify for treatment with the new complement inhibitors. Through the point-counterpoint exchange, faculty will discuss the following:
Upon completion of this activity, learners will be able to:
View Full Course